iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting
December 03 2018 - 08:00AM
iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of
biotherapeutics, today announced that it will present at the
Plant-Based Technology Trends Meeting being held in Meireles,
Fortaleza, Brazil from December 2-4, 2018. The meeting is sponsored
by Bio-Manguinhos/Fiocruz, a unit of the Brazilian Ministry of
Health.
Sancha Salgueiro, Ph.D., MBA, a well-known
expert and business development executive focussed on plant-made
protein technologies and products, will be presenting:
- Transient expression of therapeutic proteins in plants:
a flexible platform for fast and affordable biologics
manufacturing
- Date and Time: December 4, 2018; 10:00 AM BRT
- Location: Fiocruz-CE Auditorium, Rua São José, s/n. Precabura,
Eusébio-CE, Brazil
“I am honored to have this opportunity to
highlight the significant product flexibility, time- and
cost-savings provided by iBio’s plant-based technology platform and
CDMO offering to my fellow researchers and industry participants
and, in so doing, help support the development of new business
relationships and commercial collaborations for iBio in Brazil and
internationally,” said Dr. Salgueiro.
“We are pleased to be invited to present at this
international conference focusing on the latest advances and
achievements in the field of plant-based biopharmaceutical
development and manufacture of recombinant antibodies and
vaccines,” said Robert B. Kay, iBio’s Chairman and CEO. “We look
forward to continuing our collaborative relationship with
Bio-Manguinhos/Fiocruz as it implements its planned, important
expansion of capabilities in the plant-based biopharmaceutical
field.”
About iBio, Inc.
iBio, a leader in developing plant-based
biopharmaceuticals, provides a range of product and process
development, analytical, and manufacturing services at the
large-scale development and manufacturing facility of its
subsidiary iBio CDMO, LLC in Bryan, Texas. The facility
houses laboratory and pilot-scale operations, as well as
large-scale automated hydroponic systems capable of growing over
four million plants as "in process inventory" and delivering over
300 kilograms of therapeutic protein pharmaceutical active
ingredient per year. For more information please visit
www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Contact:
Stephen KilmerInvestor Relations(646) 274-3580
skilmer@ibioinc.com
Source: iBio, Inc.
iBio (AMEX:IBIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2023 to Mar 2024